January 20, 2023
Speaking of semaglutide…
Semaglutide seems to be everywhere. News stories in The Wall Street Journal. Vanity Fair. The New York Times.
January 20, 2023
Are the compounding gods listening?
With release of the revised USP <797>, the compounding gods have spoken. But like Job in the Bible, we’ve got questions.
January 20, 2023
2023 APC committee leaders named
We welcome and congratulate these 2023 leaders of APC’s standing committees...
January 20, 2023
Assess yourself: Is your expertise up-to-date?
Are you up-to-speed on recent regulatory and practice protocol changes? Take a moment to assess yourself—and to see how you measure up with your peers…
January 13, 2023
Associations write FDA about suspension shortages
APHA, NCPA, and APC sent a joint letter to FDA this week, urging the agency to take action on suspension shortages.
January 13, 2023
Compounding directives included in FDA appropriation
The report that accompanies the FDA appropriation bill recently signed by President Biden includes several compounding directives for the agency.
January 13, 2023
APC Member: “OutcomeMD delivers PROs!”
APC member TW Taylor with Williamsburg Drug in Williamsburg, VA, has been using Outcome MD for nearly nine months, and he reports that, so far, the platform has been an excellent resource for his compounding pharmacy.
January 13, 2023
Premiering: Short advocacy update vids from APC
This week we debut “What We’re Working on Right Now,” the first in what will be an ongoing series of short videos (under 4 minutes!) designed to keep our members in the know on APC’s advocacy activities.
January 6, 2023
Now open: Owner Summit registration
APC’S Owner Summit 2023 is the year's premier in-person learning, planning, and idea-sharing event for compounding pharmacy owners and managers.
January 6, 2023
Share our DTE comment letter with your BOPs
APC recently submitted a comment letter on DTE to the FDA docket outlining our concerns with the recent reclassification of DTE.
